0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessActivity-based protein profiling (ABPP) is a versatile strategy for enabling identification and characterization of new functional protein sites and discovery of lead compounds for therapeutic development. Yet, the vast majority of ABPP methods applied for covalent drug discovery target highly nucleophilic amino acids such as cysteine or lysine. Here, we report a methionine-directed ABPP platform using Redox-Activated Chemical Tagging (ReACT), which leverages a biomimetic oxidative ligation strategy for selective methionine modification. Application of ReACT to the cancer-driver protein cyclin-dependent kinase 4 (CDK4) as a representative high-value drug target identified three new hyperreactive, ligandable methionine residues, including an allosteric M169 site that is proximal to an activating T172 phosphorylation site. With this information in hand, we designed and synthesized a new methionine-targeting covalent ligand library based on oxaziridine fragments bearing a diverse array of heterocyclic, heteroatom, and stereochemically-rich substituents. ABPP screening of this focused library against a clickable broad-spectrum ReACT probe identified 1oxF11 as a covalent modifier of the CDK4/Cyclin-D1 heterodimer at the M169 site. This compound inhibited CDK4 kinase activity in a dose-dependent manner on purified protein and in live cells. Further biochemical analyses with a phospho-specific CDK4 antibody revealed crosstalk between M169 oxidation and T172 phosphorylation upon 1oxF11 treatment, where M169 oxidation prevented phosphorylation of the activating T172 site on CDK4 and blocked cell cycle progression at the S-phase checkpoint. By identifying a new mechanism for allosteric methionine redox regulation on CDK4 and developing a unique modality for its therapeutic intervention, this work showcases a generalizable platform that provides a starting point for engaging in broader chemoproteomics and protein ligand discovery efforts to find and target previously undruggable methionine sites.
Audrey G. Reeves, Angel Gonzalez-Valero, Patrick J. Moon, Edward Y. Miller, Katia Coulonval, Steven W. M. Crossley, Xiao Xie, Dan He, Patricia Z. Musacchio, Alec H. Christian, Jeffrey M. McKenna, Richard Lewis, Eric Fang, Dustin Dovala, Yipin Lu, Lynn M. McGregor, Markus Schirle, John A. Tallarico, Pierre Roger, Dean Toste, Christopher J. Chang (2022). An Activity-Based Oxaziridine Platform for Identifying and Developing Covalent Ligands for Functional Allosteric Methionine Sites: Redox-Dependent Inhibition of Cyclin-Dependent Kinase 4. , DOI: https://doi.org/10.26434/chemrxiv-2022-9p94z.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Preprint
Year
2022
Authors
21
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.26434/chemrxiv-2022-9p94z
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access